| A comprehensive review on miR-146a molecular mechanisms in a wide spectrum of immune and non-immune inflammatory diseases SS Mortazavi-Jahromi, M Aslani, A Mirshafiey Immunology Letters 227, 8-27, 2020 | 40 | 2020 |
| A controlled, randomized phase II clinical trial for efficacy and safety evaluation of mannuronic acid in secondary progressive form of multiple sclerosis S Najafi, NB Moghadam, P Saadat, SM Noorbakhsh, AV Mohammadi, ... International Journal of Neuroscience 132 (4), 403-412, 2022 | 5 | 2022 |
| A live vector expressing HPV16 L1 generates an adjuvant-induced antibody response in-vivo Z Shirbaghaee, A Bolhassani, A Mirshafiey, F Motevalli, N Zohrei Iranian Journal of Cancer Prevention 8 (6), 2015 | 4 | 2015 |
| A phase I/II randomized, controlled, clinical trial for assessment of the efficacy and safety of β-d-mannuronic acid in rheumatoid arthritis patients H Ahmadi, AR Jamshidi, F Gharibdoost, M Mahmoudi, N Rastkari, ... Inflammopharmacology 26, 737-745, 2018 | 20 | 2018 |
| A randomized clinical trial for the assessment of the efficacy and safety of guluronic acid (G2013) in patients with rheumatoid arthritis S Khadem Azarian, M Akhlaghi, M Mahmoudi, S Mostafaei, AR Jamshidi, ... Immunopharmacology and immunotoxicology 41 (1), 95-101, 2019 | 8 | 2019 |
| A randomized, controlled, phase II clinical trial of β‐D‐mannuronic acid (M2000) in pre‐surgical breast cancer patients at early stage (T1‐T2) S Kashefi, R Omranipour, H Mahmoodzadeh, H Ahmadi, A Alikhassi, ... Clinical and Experimental Pharmacology and Physiology 46 (6), 527-532, 2019 | 6 | 2019 |
| A review on defects of dendritic cells in common variable immunodeficiency L Sharifi, N Tavakolinia, F Kiaee, N Rezaei, M Mohsenzadegan, G Azizi, ... Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug …, 2017 | 17 | 2017 |
| Abnormality of regulatory T cells in common variable immunodeficiency G Azizi, N Hafezi, H Mohammadi, R Yazdani, T Alinia, M Tavakol, ... Cellular immunology 315, 11-17, 2017 | 44 | 2017 |
| Alginate and its comonomer mannuronic acid: medical relevance as drugs A Mirshafiey, BHA Rehm Alginates: biology and applications, 229-260, 2009 | 35 | 2009 |
| Alteration in frequency and function of CD4+ CD25+ FOXP3+ regulatory T cells in patients with immune thrombocytopenic purpura N Arandi, A Mirshafiey, TM JEDDI, M Shaghaghi, B Sadeghi, ... IRANIAN JOURNAL OF ALLERGY, ASTHMA AND IMMUNOLOGY (IJAAI) 13 (2), 85-92, 2014 | 55 | 2014 |
| Altered pattern of Naïve and memory B cells and B1 cells in patients with chronic granulomatous disease M Mohsenzadegan, F Fattahi, F Fattahi, A Mirshafiey, MR Fazlollahi, ... Iranian Journal of Allergy Asthma and Immunology 13 (3), 157-165, 2014 | 15 | 2014 |
| An in vitro assessment for evaluating the efficiency of β‐d‐mannuronic acid (M2000) in myelodysplastic syndrome T Bakhtiari, A Ghaderi, SR Safaee Nodehi, Z Aghazadeh, ... Journal of cellular physiology 234 (8), 12971-12977, 2019 | 7 | 2019 |
| An in vitro evaluation of anti-aging effect of guluronic acid (G2013) based on enzymatic oxidative stress gene expression using healthy individuals PBMCs M Taeb, SS Mortazavi-Jahromi, A Jafarzadeh, MR Mirzaei, A Mirshafiey Biomedicine & Pharmacotherapy 90, 262-267, 2017 | 22 | 2017 |
| An Insight into the Health Benefits of Sodium Alginate and its Derivatives L Sharifi, MR Nowroozi, S Bokaie, G Smirnova, A Fedotova, D Babarykin, ... Biomedical Journal of Scientific & Technical Research 55 (3), 46971-46979, 2024 | | 2024 |
| Analysis of Lymphocyte and Clinical Profile among Non-monogenic Common Variable Immunodeficiency Patients with and without Class Switch Recombination Defect A Mirshafiey, A Aghamohammadi J Investig Allergol Clin Immunol 33 (6), 2023 | | 2023 |
| Analysis of Lymphocyte and Clinical Profile in Nonmonogenic Common Variable Immunodeficiency Patients With and Without Class Switch Recombination Defect FT Zavareh, A Mirshafiey, R Yazdani, AA Keshtkar, H Abolhassani, ... Journal of investigational allergology & clinical immunology 33 (6), 474-476, 2023 | | 2023 |
| Antagonistic Property of G2013 (α-L-Guluronic Acid) on Gene Expression of MyD88, Tollip, and NF-ΚB in HEK293 TLR2 and HEK293 TLR4 L Sharifi, A Aghamohammadi, S Aletaha, R Bigdeli, V Asgary, S Bokaie, ... Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug …, 2019 | 3 | 2019 |
| Anti-aging effects of M2000 (β-D-mannuronic acid) as a novel immunosuppressive drug on the enzymatic and non-enzymatic oxidative stress parameters in an experimental model S Hosseini, M Abdollahi, G Azizi, MJ Fattahi, N Rastkari, FT Zavareh, ... Journal of basic and clinical physiology and pharmacology 28 (3), 249-255, 2017 | 17 | 2017 |
| Anti-aging property of G2013 molecule as a novel immunosuppressive agent on enzymatic and non-enzymatic oxidative stress determinants in rat model A Mirshafiey, S Hosseini, S Afraei, N Rastkari, F T Zavareh, G Azizi Current drug discovery technologies 13 (1), 25-33, 2016 | 27 | 2016 |
| Anti-Diabetic and Angio-Protective Effect of Guluronic Acid (G2013) as a New Nonsteroidal Anti-Inflammatory Drug in the Experimental Model of Diabetes SS Mortazavi-Jahromi, S Alizadeh, MH Javanbakht, A Mirshafiey Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug …, 2020 | 1 | 2020 |
